Home > News > AMSBIO Introduced a New Range of Homogeneous Proximity Assays
Industry Updates New Products Supplier News Upcoming Events business web

AMSBIO Introduced a New Range of Homogeneous Proximity Assays

Hits:310   Date: 7/19/2019
Targeted Protein Degradation for Drug Discovery

AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).

Targeted protein degradation using PROTACs is a new and promising therapeutic method in drug discovery. PROTACs have the ability to regulate protein degradation through targeted control of ubiquitin E3 ligases. This novel technology allows for the degradation of disease-related proteins and offers many advantages over traditional protein inhibition.

The PROTAC method offers many advantages compared to traditional protein inhibition. Inhibitors require sustained protein binding to evoke the intended biological reaction. This can be problematic in the incidence of target overexpression, the presence of competing ligands, or protein mutations that lead to binding resistance. The PROTAC model bypasses these issues by promoting degradation that circumvents the native resistance of proteins against sustained inhibition.

Even select weak binding and promiscuous ligands can be used with PROTACs and still demonstrate high degradation efficacy. Also, ineffectual ligands which do not modulate the cellular functions of the protein of interest can be used to mediate degradation through PROTACs. Whether the ligand is a strong inhibitor, a weak binder, promiscuous, or ineffectual, PROTACs offer the ability to degrade proteins previously believed to be 'undruggable' through conventional small molecule inhibition.

For further information please visit http://www.amsbio.com/proteolysis-targeting-chimera.aspx or contact AMSBIO on 44-1235-828200/+1-617-945-5033 /info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. 

For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.  

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com  
Web www.amsbio.com
North American HQ
1035 Cambridge Street
MA 02141
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com
Tel:+44 (0) 1235 828 200